Drug Trial Radar · NCT05337566
Does Additional Use of Preoperative Azithromycin Decrease Posthysterectomy Infections
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,278
Planned (sponsor's estimate)
Start
Sep 5, 2022
Primary completion
Dec 31, 2027
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Helsinki University Central HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Turku; Tampere University Hospital; Kuopio University Hospital; Oulu University Hospital; Jyväskylä Central Hospital
- First posted
- Apr 20, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
During hysterectomy bacteria may enter into the peritoneal cavity through vaginal opening and contaminate the healing tissues. The risk for deep infection after hysterectomy is about 5%. By reducing post-hysterectomy infections, it is possible to reduce individual burden of disease in addition to the direct and indirect financial costs. This study primary aim is to assess if prophylactic preoperative use of azithromycin in addition to generally used cefuroxime decreases post-hysterectomy infections as compared to cefuroxime only prophylaxis during 30 days after hysterectomy. Secondary aim is to assess if there is change in post-hysterectomy superficial infections, urinary tract infections, or post-operative fever between the cohorts and to report possible side-effects of the used antibiotics. In addition, the study finds out a possible role of bacterial vaginosis and microbiome n post-hysterectomy infections.
Conditions
- Infection Post Op
- Hysterectomy
- Antibiotics
- Prophylactic
Interventions
Azithromycin Pill + CefuroximeDrug
Azithromycin 500 mg (2 tablets) per orally when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
Placebo + CefuroximeDrug
Placebo (2 tablets) per orally in the evening when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of post-hysterectomy episodes with deep infectionsTime frame: Deep infections that occur between the first and 30th postoperative day after hysterectomy
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Helsinki University Central Hospital
Helsinki, Finland · Recruiting
Jyväskylä Central Hospital
Jyväskylä, Finland · Recruiting
Kuopio University Central Hospital
Kuopio, Finland · Recruiting
Oulu University Central Hospital
Oulu, Finland · Recruiting
Tampere University Central Hospital
Tampere, Finland · Recruiting
Turku University Central Hospital
Turku, Finland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.